Related Experiment Video
Updated: May 10, 2026
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
10.7K
Albumin and multiple sclerosis: a prospective study from UK Biobank
Ke Chen1,2, Chunyu Li1, Bi Zhao1
1Department of Neurology, Laboratory of Neurodegenerative Disorders, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Frontiers in Immunology
|June 25, 2024
Summary
Higher serum albumin levels are linked to a reduced risk of developing multiple sclerosis (MS). This finding may help identify individuals at lower risk and inform future therapeutic strategies for MS.
Area of Science:
- Neuroimmunology
- Biochemistry
- Epidemiology
Background:
- Multiple sclerosis (MS) is a chronic central nervous system inflammatory disease.
- Albumin's role in neuroinflammation and neurodegenerative disorders is recognized, but its specific association with MS risk is underexplored.
Purpose of the Study:
- To investigate the association between baseline serum and urine albumin levels and the risk of developing MS.
- To explore potential biomarker utility of albumin in MS.
Main Methods:
- Utilized UK Biobank data for a large-scale cohort study.
- Employed Cox proportional hazards regression analysis to assess risk associations.
- Analyzed both serum and urine albumin levels.
Main Results:
- Elevated serum albumin levels were significantly associated with a reduced risk of incident MS (HR=0.94, P=7.66E-04).
- This protective association was more pronounced in females, younger individuals, non-smokers, and those with vitamin D deficiency.
- No significant association was found between urine albumin (microalbuminuria) and MS risk.
Conclusions:
- Higher baseline serum albumin is linked to lower MS risk, suggesting a potential protective role.
- Serum albumin may serve as a predictive biomarker for MS risk.
- Findings have implications for understanding MS pathogenesis and developing albumin-targeted therapies.
